Rallybio Director Exercises Options for 8,482 Shares

Q: What option exercises did RLYB director Hui Liu report?

Hui Liu reported exercising options for 3,562 Rallybio common shares at $2.38 per share and 8,482 shares at $7.60 per share on September 24, 2026. The corresponding common-stock entries report acquisition of those same share amounts.

Q: What was the vesting schedule for Hui Liu's RLYB option?

The option vested as to the underlying shares in 12 equal installments, each on the last day of each month of calendar year 2025.

One exercised option was issued under Rallybio's 2021 Equity Incentive Plan in lieu of $47,500 in retainer fees.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rallybio Corp (RLYB) director Hui Liu exercised options to acquire 3,562 and 8,482 common shares on September 24, 2026, at exercise prices of $2.38 and $7.60 per share, respectively. The corresponding common-stock entries report acquisition of those same share amounts. The 8,482-share option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $47,500 in retainer fees.

Insider Trade Summary

12,044 shares exercised/converted

Exercise 4 txns

Insider Liu Hui

Role Director

Type	Security	Shares	Price	Value
Exercise	Option (Right to Buy)	3,562	$0.00	$0.00
Exercise	Option (Right to Buy) ^{F2, F1}	8,482	$5.60	$47K
Exercise	Common Stock	3,562	$2.38	$8K
Exercise	Common Stock	8,482	$7.60	$64K

Holdings After Transaction: Option (Right to Buy) — 0 contracts (Direct); Common Stock — 12,044 shares (Direct)

Footnotes (2)

F1. The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.
F2. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $47,500.

Key Figures

Options exercised for common shares: 3,562 shares Exercise price: $2.38 per share Options exercised for common shares: 8,482 shares +2 more

5 metrics

Options exercised for common shares 3,562 shares September 24, 2026; exercise price $2.38 per share

Exercise price $2.38 per share Option covering 3,562 common shares

Options exercised for common shares 8,482 shares September 24, 2026; exercise price $7.60 per share

Exercise price $7.60 per share Option covering 8,482 common shares

Retainer fees $47,500 Value of fees in lieu of which the 8,482-share option was issued

Key Terms

Option (Right to Buy), 2021 Equity Incentive Plan, retainer fees

3 terms

Option (Right to Buy) financial

"Option (Right to Buy)"

2021 Equity Incentive Plan financial

"issued pursuant to the Company's 2021 Equity Incentive Plan"

retainer fees financial

"in lieu of retainer fees of $47,500"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option exercises did RLYB director Hui Liu report?

Hui Liu reported exercising options for 3,562 Rallybio common shares at $2.38 per share and 8,482 shares at $7.60 per share on September 24, 2026. The corresponding common-stock entries report acquisition of those same share amounts.

What was the vesting schedule for Hui Liu's RLYB option?

The option vested as to the underlying shares in 12 equal installments, each on the last day of each month of calendar year 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/28/2026 - 09:01 PM Accepted by SEC EDGAR 09/28/2026 - 09:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Hui

(Last)

(First)

(Middle)

C/O RALLYBIO CORPORATION

PO BOX 325

(Street)

EAST BERLIN

CONNECTICUT

06023

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rallybio Corp [ RLYB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/24/2026		M		3,562	A	$2.38	3,562	D
Common Stock	09/24/2026		M		8,482	A	$7.6	12,044	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (Right to Buy)	$2.38	09/24/2026		M			3,562	05/13/2026	05/13/2035	Common Stock	3,562	$0.00	0	D
Option (Right to Buy)	$7.6	09/24/2026		M			8,482	⁽¹⁾	01/02/2035	Common Stock	8,482	$5.6⁽²⁾	0	D

Explanation of Responses:

1. The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.

2. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $47,500.

	By: /s/ Jonathan Lieber, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR